XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

Company Overview

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Key Stats

• Today's Range: $1.13 to $1.13
• 50-Day Range: $3.43 to $5.20
• 52-Week Range: $0.86 to $3.05
• Volume: N/A
• Average Volume: 24,100 shs
• Market Capitalization: $8.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XTL Biopharmaceuticals Stock Analysis - MarketRank™

XTL Biopharmaceuticals scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for XTL Biopharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

XTL Biopharmaceuticals has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of XTL Biopharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

XTL Biopharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in XTL Biopharmaceuticals has recently decreased by 92.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XTL Biopharmaceuticals does not currently pay a dividend.

Dividend Growth

XTL Biopharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of XTL Biopharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

XTL Biopharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in XTL Biopharmaceuticals has recently decreased by 92.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for XTL Biopharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.40% of the stock of XTL Biopharmaceuticals is held by institutions.

XTLB Stock Analysis - Frequently Asked Questions

How were XTL Biopharmaceuticals' earnings last quarter?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) issued its earnings results on Monday, December, 30th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter.

When did XTL Biopharmaceuticals' stock split?

XTL Biopharmaceuticals shares reverse split on Friday, February 10th 2017.The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of XTL Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP).

Company Calendar

• Last Earnings: 12/30/2024
• Today: 7/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XTLB
• CIK: 1023549
• Web: www.xtlbio.com
• Phone: (729) 955-7080
• Fax: 972-3611-6605
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: $450 thousand
• Price / Sales: 18.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 5,450,000
• Free Float: 3,869,000
• Market Cap: $8.20 million
• Optionable: Not Optionable
• Beta: 1.05